Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.76 |
| ▸ | S1PR1 | P21453 | 14/20 | 0.76 |
| ▸ | PRKX | P51817 | 2/20 | 0.72 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.59 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.59 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044904 | 0.86 | S1PR1 (1.00) | S1PR5S1PR1PRKXACVR1PRKD3 | |
| SCHEMBL3040329 | 0.84 | S1PR5 (1.00) | S1PR5S1PR1PRKXACVR1PRKD3 | |
| SCHEMBL3041369 | 0.84 | S1PR5 (0.77) | S1PR5S1PR1PRKXACVR1PRKD3 | |
| SCHEMBL1873631 | 0.83 | S1PR1 (0.82) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL3047297 | 0.81 | S1PR5 (0.62) | S1PR5S1PR1PRKXACVR1PDCD1 | |
| SCHEMBL3043859 | 0.80 | S1PR5 (0.78) | S1PR5S1PR1PDCD1CD274S1PR4 | |
| SCHEMBL3034496 | 0.80 | S1PR5 (1.00) | S1PR5S1PR1PRKXACVR1PDGFRA | |
| SCHEMBL22083846 | 0.79 | S1PR1 (0.60) | S1PR5S1PR1PRKXPRKD3CDK7 | |
| SCHEMBL22084567 | 0.78 | S1PR1 (0.61) | S1PR5S1PR1PRKXPRKD3CDK7 | |
| SCHEMBL22083855 | 0.78 | S1PR1 (0.53) | S1PR5S1PR1PRKXACVR1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | claimed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | claimed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | claimed |
| CN-102387704-A | Agonists and antagonists of the S1P5 receptor, and methods of uses thereof | ABBOTT LAB | 2012-03-21 | — | — | CN | disclosed |
| EP-2395835-A1 | AGONISTS AND ANTAGONISTS OF THE SIP5 RECEPTOR, AND METHODS OF USES THEREOF | Abbott Laboratories (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093704-A1 | AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF | ABBOTT LABORATORIES (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | S1PR5 1/4885S1PR1 3/4885PRKX 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.